CN105745223A - 修饰的抗炎蛋白及使用方法 - Google Patents

修饰的抗炎蛋白及使用方法 Download PDF

Info

Publication number
CN105745223A
CN105745223A CN201480061261.2A CN201480061261A CN105745223A CN 105745223 A CN105745223 A CN 105745223A CN 201480061261 A CN201480061261 A CN 201480061261A CN 105745223 A CN105745223 A CN 105745223A
Authority
CN
China
Prior art keywords
tmp
disease
protein
modified
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480061261.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·劳卡斯
安德鲁·里奇
达雷·皮克尔灵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
James Cook University
Original Assignee
James Cook University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903588A external-priority patent/AU2013903588A0/en
Application filed by James Cook University filed Critical James Cook University
Publication of CN105745223A publication Critical patent/CN105745223A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480061261.2A 2013-09-18 2014-09-18 修饰的抗炎蛋白及使用方法 Pending CN105745223A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013903588A AU2013903588A0 (en) 2013-09-18 Modified anti-inflammatory proteins and method of use
AU2013903588 2013-09-18
PCT/AU2014/050240 WO2015039189A1 (en) 2013-09-18 2014-09-18 Modified anti-inflammatory proteins and method of use

Publications (1)

Publication Number Publication Date
CN105745223A true CN105745223A (zh) 2016-07-06

Family

ID=52688012

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480061261.2A Pending CN105745223A (zh) 2013-09-18 2014-09-18 修饰的抗炎蛋白及使用方法

Country Status (8)

Country Link
US (3) US10822395B2 (enExample)
EP (2) EP4509188A3 (enExample)
JP (1) JP2016532456A (enExample)
CN (1) CN105745223A (enExample)
AU (1) AU2014324094B2 (enExample)
CA (1) CA2924220A1 (enExample)
WO (1) WO2015039189A1 (enExample)
ZA (1) ZA201602304B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105745223A (zh) * 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
WO2022192955A1 (en) * 2021-03-17 2022-09-22 James Cook University Proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842788B2 (en) * 1993-10-06 2010-11-30 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
DE69233035D1 (de) 1991-12-24 2003-06-05 Harvard College Gezielte punkt-mutagenese von dna
US6756211B1 (en) 1992-05-11 2004-06-29 Corvas International, Inc. Neutropohil inhibitors
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
WO1999047070A1 (en) 1998-03-18 1999-09-23 Wake Forest University Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
JP2000007575A (ja) 1998-06-17 2000-01-11 Fuji Chem Ind Ltd 抗アレルギー剤
AU2001252278A1 (en) 2000-04-05 2001-10-15 Ipf Pharmaceuticals Gmbh Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
JP4426179B2 (ja) 2000-12-18 2010-03-03 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
DE10138550A1 (de) 2001-08-06 2003-02-20 Wolfgang E Berdel Verwendung von TIMP-1 als Immunsuppressivum
US7303752B2 (en) 2001-10-17 2007-12-04 The George Washington University Hookworm vaccine
NZ536796A (en) 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
US7928132B2 (en) 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
WO2007005672A2 (en) 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
EP1910417A2 (en) 2005-07-29 2008-04-16 Imperial Innovations Limited Compounds
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US9637527B2 (en) * 2012-03-13 2017-05-02 James Cook University Method for treating inflammation with an Ac-TMP-2 protein
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
CN105745223A (zh) 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
AU2014324093A1 (en) * 2013-09-18 2016-04-28 James Cook University Anti-inflammatory proteins and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842788B2 (en) * 1993-10-06 2010-11-30 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHAN B等: "Molecular cloning and characterization of Ac-TMP-2, a tissue inhibitor of metalloproteinase secreted by adult Ancylostoma caninum.", 《MOL BIOCHEM PARASITOL.》 *

Also Published As

Publication number Publication date
CA2924220A1 (en) 2015-03-26
US20160229905A1 (en) 2016-08-11
ZA201602304B (en) 2019-06-26
US12466873B2 (en) 2025-11-11
US11976108B2 (en) 2024-05-07
WO2015039189A1 (en) 2015-03-26
US10822395B2 (en) 2020-11-03
US20240400649A1 (en) 2024-12-05
JP2016532456A (ja) 2016-10-20
US20210061886A1 (en) 2021-03-04
EP4509188A3 (en) 2025-04-02
AU2014324094A1 (en) 2016-05-05
AU2014324094B2 (en) 2019-03-14
EP3046937A4 (en) 2017-04-26
EP3046937A1 (en) 2016-07-27
EP4509188A2 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
Akdis et al. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens
TWI784988B (zh) 治療發炎症狀的方法
Spohn et al. Active immunization with IL‐1 displayed on virus‐like particles protects from autoimmune arthritis
Trujillo-Vargas et al. Helminth-derived products inhibit the development of allergic responses in mice
US12466873B2 (en) Modified anti-inflammatory proteins and method of use
JP6671069B2 (ja) 炎症性疾患の予防又は治療剤
WO2013160865A1 (en) Immunotolerizing fusion proteins for treatment of multiple sclerosis
JP2018508522A (ja) 抗炎症性ポリペプチド
WO2008148306A1 (fr) Vaccin prophylactique et/ou thérapeutique contre l'asthme allergique
CN104411325B (zh) 用于治疗炎症的方法
CN101921325B (zh) 一种增加CD4+CD25+Foxp3+调节性T细胞的抗原及其应用
JP2010535504A5 (enExample)
CN106540242B (zh) IL-1F7a的作用
WO2015077442A2 (en) Grass pollen immunogens and methods and uses for immune response modulation
JP2021515744A (ja) ＩｇＥ媒介型アレルギー性疾患治療のための、膜結合型ＩｇＥを標的とするペプチド免疫原及びそれらの製剤
Taoa et al. Th1-type epitopes-based cocktail PDDV attenuates hepatic fibrosis in C57BL/6 mice with chronic Schistosoma japonicum infection
US9023841B2 (en) Compositions and methods for the treatment of asthma and associated disorders
AU2014352986A1 (en) Pan pollen immunogens and methods and uses thereof for immune response modulation
Singh et al. Immune response to n-terminal and c-terminal deletion mutants of Aspergillus fumigatus major allergen ASP F 3
US20180118795A1 (en) Dendritic cell inhibitory proteins from ticks
WO2015054210A2 (en) T. suis excretory/secretory products and methods of their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160706